Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors

Patent metadata

Field	Value
Publication number	US-9694014-B2
Application number	US-201313942448-A
Country	US
Kind code	B2
Filing date	Jul 15, 2013
Priority date	Jun 22, 2011
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein.

First claim

What is claimed is:

1. A method of inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species which method comprises contacting the cell with an effective amount of a monoamine oxidase B inhibitor compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A method for treating muscle dystrophy wherein the etiology of said muscle dystrophy includes overproducing reactive oxygen species which method comprises administering a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof; and
wherein the compound reduces or prevents the production of reactive oxygen species, thereby treating muscle dystrophy.

Assignees

• Univ Degli Studi Padova

Inventors

• Bonaldo Paolo
• Canton Marcella
• Dilisa Fabio
• Menazza Sara

Classifications

• A61K31/5375 Primary

  1,4-Oxazines, e.g. morpholine · CPC title

• A61K31/42

  Oxazoles · CPC title

• A61K31/36

  Compounds containing methylenedioxyphenyl groups, e.g. sesamin · CPC title

• A61K31/44

  Non condensed pyridines; Hydrogenated derivatives thereof · CPC title

• A61K31/4985

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title